盐酸安罗替尼治疗晚期非小细胞肺癌的近期效果及安全性  

Short-term efficacy and safety of Anlotinib Hydrochloride in the treatment of advanced non-small cell lung cancer

作　　者：宛新安[1] 周勤[1] 李卓芳 陈昊[1] 刁海霞 WAN Xin’an;ZHOU Qin;LI Zhuofang;CHEN Hao;DIAO Haixia(Department of Oncology and Radiotherapy,the Second People’s Hospital of Wuhu City,Anhui Province,Wuhu 241000,China)

机构地区：[1]安徽省芜湖市第二人民医院肿瘤放疗科,安徽芜湖241000

出　　处：《中国医药导报》2022年第20期112-115,共4页China Medical Herald

摘　　要：目的探究盐酸安罗替尼治疗晚期非小细胞肺癌(NSCLC)的近期效果及安全性。方法选取安徽省芜湖市第二人民医院于2018年6月至2021年5月收治的二线及以上治疗的80例晚期NSCLC患者,根据随机数字表法将其分为两组,各40例。观察组给予盐酸安罗替尼治疗,对照组给予最佳支持治疗。治疗6周,比较两组的近期疗效[客观缓解率(ORR)、疾病控制率(DCR)],癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平,观察两组卡氏功能状态(KPS)评分及不良反应。结果治疗后,观察组ORR、DCR高于对照组(P<0.05)。治疗后,两组CEA、CYFRA21-1水平低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组KPS评分高于治疗前,且观察组高于对照组(P<0.05)。观察组手足综合征、蛋白尿、高血压、口腔黏膜炎的发生率高于对照组(P<0.05)。结论盐酸安罗替尼治疗NSCLC的近期效果显著,安全性良好,可为治疗失败NSCLC患者提供新的治疗手段,值得推广应用。Objective To explore the short-term efficacy and safety of Anlotinib Hydrochloride in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Eighty patients with advanced NSCLC treated at the second line and above in the Second People’s Hospital of Wuhu City in Anhui Province from June 2018 to May 2021 were selected and they were divided into two groups according to random number table method,with 40 cases in each group.The observation group was treated with Anlotinib Hydrochloride,and the control group was given the best supportive treatment.After six weeks of treatment,the short-term curative effects(objective remission rate[ORR],disease control rate[DCR]),the levels of carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)were compared between two groups.Karnofsky performance status(KPS)score and adverse reactions were observed in two groups.Results After treatment,ORR and DCR of observation group were higher than those of control group(P<0.05).After treatment,the levels of CEA and CYFRA21-1 in two groups were lower than those before treatment(P<0.05),and observation group was lower than control group(P<0.05).After treatment,KPS scores of two groups were higher than those before treatment(P<0.05),and those of observation group were higher than control group(P<0.05).The incidence rates of hand foot syndrome,proteinuria,hypertension,and oral mucositis in observation group were higher than those in control group(P<0.05).Conclusion Anlotinib Hydrochloride has significant short-term efficacy and good safety in the treatment of NSCLC,and it can provide a new treatment for NSCLC patients with treatment failure,which is worthy of popularization and application.

关 键 词：晚期非小细胞肺癌 安罗替尼 近期疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]